Application of Metabolomics for Translational and Biological Research (R21) | Apply Online

Frequently Asked Questions (FAQs)

What is the NIH funding opportunity "Application of Metabolomics for Translational and Biological Research (R21)" (PA-07-302)?

PA-07-302 is an NIH funding opportunity that supports pilot-scale research projects using metabolomics to address practical questions in human health and disease. It is designed to encourage early, exploratory translational studies that demonstrate how metabolomics can produce findings with potential clinical or public health relevance.

What does "metabolomics" mean in the context of this FOA?

In this FOA, metabolomics refers to technologies and approaches that measure and analyze many small-molecule metabolites at once from biological samples such as cells, tissues, and body fluids. The aim is to use broad metabolite measurements to gain actionable biological or biomedical insight.

What is the central goal of PA-07-302?

The central goal is to push metabolomic approaches beyond basic measurement and into translational use. Projects are expected to move toward outcomes that could ultimately influence real-world clinical or public health decisions, rather than focusing only on technology development or descriptive profiling.

What kinds of translational outcomes does NIH emphasize for this opportunity?

The FOA highlights metabolomics applications that could improve disease detection and diagnosis, support risk and prognosis assessment, and enable better prediction of patient response to therapies. Proposed work should be framed around a practical biomedical question tied to human health and disease.

What does the NIH R21 mechanism mean for applicants?

The R21 mechanism is intended for exploratory and developmental research. For this FOA, that generally means early-stage, proof-of-concept projects; feasibility testing; method adaptation or validation for a specific biomedical question; and generating preliminary data that can justify a larger follow-on study.

What project scale and maturity is PA-07-302 designed to support?

PA-07-302 is aimed at relatively modest, time-limited pilot projects where an innovative metabolomics approach can demonstrate clear value. It is positioned for projects that are not yet ready for a larger, more comprehensive study design.

How is this R21 opportunity different from the companion R01 announcement (PA-07-301)?

The FOA runs in parallel with a companion announcement (PA-07-301) with the same scientific scope but using the R01 mechanism. The R01 is typically more appropriate for mature projects with extensive preliminary data and a more comprehensive research plan, while the R21 is intended for exploratory, early-stage work.

Do applicants have to choose between submitting an R21 (PA-07-302) and an R01 (PA-07-301)?

Yes. Based on the description, applicants choose the mechanism that best matches the maturity and scale of their proposed work: R21 for exploratory, proof-of-concept efforts and R01 for more developed, comprehensive projects.

What types of research activities are explicitly aligned with the R21 goals here?

Examples aligned with the stated intent include feasibility studies in a new clinical context, adapting or validating metabolomics methods for a specific biomedical question, and producing preliminary data to support a future larger study. The FOA frames these as ways to accelerate innovative uses of metabolomic platforms in biology and medicine.

What disease or research areas are relevant under this FOA?

The opportunity is cross-cutting across many areas reflected by the listed CFDA catalog entries. These include oral diseases; drug abuse and addiction; multiple cancer research areas (cause and prevention, detection and diagnosis, treatment, and biology); cardiovascular disease; blood diseases; diabetes and digestive and kidney diseases; and aging research.

Why are multiple NIH institutes involved?

Multiple NIH institutes participate because metabolomics is presented as a broadly applicable technology across many disease areas and biological systems. The FOA signals NIH interest in metabolomics as a way to uncover disease mechanisms, identify clinically useful biomarkers, and provide measurable readouts of physiology and therapeutic response across fields.

What kinds of samples are mentioned as suitable for metabolomics in this program?

The FOA description references biological samples such as cells, tissues, and body fluids as sources for metabolite measurement and analysis.

Is the focus on developing metabolomics technology or applying it to biomedical problems?

The emphasis is on deploying metabolomic measurement and analysis in ways that can realistically improve understanding, prediction, or management of human disease. The FOA explicitly notes that it is not focused on metabolomics as a purely technical exercise, but on translational application.

Who is eligible to apply for PA-07-302 based on the information provided?

Eligibility is broad and includes public and state-controlled institutions of higher education, private universities, small businesses, nonprofit organizations (including 501(c)(3) and certain non-501(c)(3) entities), and for-profit organizations other than small businesses. Foreign institutions are also explicitly eligible.

Are foreign (non-U.S.) institutions allowed to apply?

Yes. Foreign institutions are explicitly eligible under this opportunity, allowing international research groups to propose metabolomics-driven translational studies.

Is cost sharing or matching required?

No. The FOA states there is no cost sharing or matching requirement, meaning applicants are not required to contribute additional non-federal funds as a condition of receiving an award.

What agency administers this grant program?

This is a discretionary grant program run by the National Institutes of Health (NIH).

When was PA-07-302 posted, and what are the key dates mentioned?

The opportunity was posted on January 17, 2007. The source data lists a closing date of January 2, 2010 and an archive date of February 2, 2010.

Is PA-07-302 still active?

No. The closing date (January 2, 2010) and archive date (February 2, 2010) indicate the FOA is no longer active, although the summary can still be useful for understanding NIH priorities from that period.

Did the FOA accept applications on multiple receipt dates?

Yes. The description states it accepted applications on multiple receipt dates, with specific details provided in the full announcement.

Are awards guaranteed if a proposal is strong?

No. NIH notes that awards depend on the availability of funds and the receipt of a sufficient number of high-quality applications. This means funding decisions can be affected by budget availability and competition, even for strong proposals.

What are examples of projects that fit the overall intent of PA-07-302?

Examples described as fitting the intent include discovering or validating metabolite signatures associated with disease states, stratifying patient risk, tracking disease progression, and predicting which treatments are likely to work for which patients.

What is the overall way to interpret PA-07-302 as an NIH signal to the research community?

It is best understood as NIH encouragement for creative, translational metabolomics pilot studies that demonstrate clear biomedical relevance and potential impact, especially in biomarker development and measurable readouts tied to disease mechanisms, diagnosis, prognosis, and therapy response.